JP2022506109A5 - - Google Patents
Info
- Publication number
- JP2022506109A5 JP2022506109A5 JP2021523277A JP2021523277A JP2022506109A5 JP 2022506109 A5 JP2022506109 A5 JP 2022506109A5 JP 2021523277 A JP2021523277 A JP 2021523277A JP 2021523277 A JP2021523277 A JP 2021523277A JP 2022506109 A5 JP2022506109 A5 JP 2022506109A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- subject
- blood
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752510P | 2018-10-30 | 2018-10-30 | |
| US62/752,510 | 2018-10-30 | ||
| PCT/US2019/058898 WO2020092594A1 (en) | 2018-10-30 | 2019-10-30 | Therapeutic compounds and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506109A JP2022506109A (ja) | 2022-01-17 |
| JP2022506109A5 true JP2022506109A5 (enExample) | 2022-10-28 |
Family
ID=70464743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523277A Pending JP2022506109A (ja) | 2018-10-30 | 2019-10-30 | 治療用化合物および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210253550A1 (enExample) |
| EP (1) | EP3873446A4 (enExample) |
| JP (1) | JP2022506109A (enExample) |
| KR (1) | KR20210084581A (enExample) |
| CN (1) | CN113056263A (enExample) |
| AU (1) | AU2019369518A1 (enExample) |
| BR (1) | BR112021008462A2 (enExample) |
| CA (1) | CA3117549A1 (enExample) |
| IL (1) | IL282765A (enExample) |
| WO (1) | WO2020092594A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2733405C2 (ru) | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| CA3089970A1 (en) | 2018-02-07 | 2019-08-15 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| TW202345825A (zh) * | 2022-03-30 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | 環狀內醯胺類化合物的注射用藥物組合物及其製備方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| EP1871741A4 (en) * | 2005-04-04 | 2012-01-11 | Daiamed Inc | SUBSTITUTED AZETIDINONE |
| JP6033319B2 (ja) * | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| RU2733405C2 (ru) * | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| US20190315711A1 (en) * | 2016-12-23 | 2019-10-17 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| JP2022506110A (ja) * | 2018-10-30 | 2022-01-17 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
| JP2022523712A (ja) * | 2019-01-29 | 2022-04-26 | エクセセーラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物および組成物 |
-
2019
- 2019-10-30 CN CN201980072155.7A patent/CN113056263A/zh active Pending
- 2019-10-30 EP EP19880599.6A patent/EP3873446A4/en active Pending
- 2019-10-30 JP JP2021523277A patent/JP2022506109A/ja active Pending
- 2019-10-30 KR KR1020217016347A patent/KR20210084581A/ko not_active Withdrawn
- 2019-10-30 BR BR112021008462-2A patent/BR112021008462A2/pt unknown
- 2019-10-30 WO PCT/US2019/058898 patent/WO2020092594A1/en not_active Ceased
- 2019-10-30 AU AU2019369518A patent/AU2019369518A1/en not_active Abandoned
- 2019-10-30 CA CA3117549A patent/CA3117549A1/en active Pending
-
2021
- 2021-04-28 IL IL282765A patent/IL282765A/en unknown
- 2021-04-30 US US17/245,691 patent/US20210253550A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506110A5 (enExample) | ||
| JP2022506109A5 (enExample) | ||
| Boereboom et al. | Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients | |
| Donckerwolcke et al. | Hemodialysis in infants and small children | |
| JP2022523712A5 (enExample) | ||
| SU1183112A1 (ru) | Способ лечени острой ишемии миокарда | |
| Buchanan | Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure | |
| Sim et al. | A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose | |
| Gaynor | Use of modified ultrafiltration after repair of congenital heart defects | |
| Rottembourg et al. | Clinical aspects of continuous ambulatory and continuous cyclic peritoneal dialysis in diabetic patients | |
| Dickson et al. | Continuous renal replacement in the critically ill | |
| Simaan et al. | A comparative study between the cardiovascular effects of cetiedil, a new vasodilator, and papaverine and aminophylline. | |
| Kaplan | Continuous renal replacement therapy (CRRT) in the intensive care unit | |
| Morgan et al. | Fluid removal by haemofiltration in diuretic resistant cardiac failure. | |
| Seltzer et al. | Decrease in arterial pressure following heparin injection prior to cardiopulmonary bypass | |
| Clar et al. | Hemofiltration: determinants of drug loss and concentration | |
| Hwang et al. | Dialytic ascitic ultrafiltration in refractory ascites. | |
| RU2021115313A (ru) | Терапевтические соединения и композиция | |
| Darling et al. | Modified ultrafiltration in pediatric cardiopulmonary bypass | |
| Vaziri et al. | Hemodialysis clearance of cimetidine | |
| Khanna et al. | Peritoneal dialysis in diabetic end-stage renal disease | |
| Liang et al. | Outcomes associated with a heparin-free hemodialysis protocol and review of the literature | |
| Mendeloff et al. | Thromboxane A2 receptor-specific antagonism in hypothermic cardiopulmonary bypass | |
| US3632765A (en) | Treatment of shock | |
| Caruso et al. | Continuous hemodialysis for the management of acute renal failure in the presence of cerebellar hemorrhage: case report |